DBV Technologies secured up to $306.9M to advance its Viaskin Peanut program. The funding supports FDA submission, commercialization and ongoing pediatric peanut allergy treatment research.
DBV Technologies secures FDA guidance for Accelerated Approval of its Viaskin Peanut patch, advancing treatment for toddlers with peanut allergies through pivotal trials.
DBV Technologies progresses with regulatory efforts for its Viaskin Peanut patch in the U.S. and Europe, while financial concerns loom as the company seeks additional funding to continue its operations.
